Revakinagene Taroretcel-Lwey
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease.
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease.
Journal: Advanced drug delivery reviews
Published: October 12, 2025
LONG-TERM PROGRESSION OF ELLIPSOID ZONE LOSS AND ASSOCIATED FEATURES ON OPTICAL COHERENCE TOMOGRAPHY IN MACULAR TELANGIECTASIA TYPE 2.
Journal: Ophthalmology
Published: August 27, 2025
Long-Term Durability of Ciliary Neurotrophic Factor-Releasing Revakinagene Taroretcel-lwey in Individuals With Retinal Degenerative Disorders.
Journal: Investigative ophthalmology & visual science
Published: August 04, 2025
Beyond the injection: delivery systems reshaping retinal disease management.
Journal: Expert opinion on pharmacotherapy
Published: May 04, 2025
Revakinagene Taroretcel: First Approval.
Journal: Molecular diagnosis & therapy
Published: April 30, 2025
Revakinagene taroretcel (Encelto) - a gene therapy for idiopathic macular telangiectasia.
Journal: The Medical letter on drugs and therapeutics
Published: April 22, 2025
Clinical histopathology and pathogenesis of macular telangiectasia type 2.
Journal: Progress in retinal and eye research
Published: August 02, 2024
Showing 1-8 of 8
Last Updated: 02/24/2026